October 20, 2014 4:54 AM ET

Pharmaceuticals

Company Overview of G1 Therapeutics, Inc.

Company Overview

G1 Therapeutics, Inc. researches and develops small molecule therapies to address unmet needs in oncology. It offers programs including G1T28-1, to protect bone marrow and other organs from side effects of chemotherapy treatments and radiation. The company was formerly known as G-Zero Therapeutics Inc. G1 Therapeutics, Inc. was founded in 2008 and is based in Research Triangle Park, North Carolina.

79 T.W. Alexander Drive

4401 Research Commons

Suite 105

Research Triangle Park, NC 27709

United States

Founded in 2008

Phone:

919-213-9835

Fax:

919-741-5830

Key Executives for G1 Therapeutics, Inc.

Chief Executive Officer and Director
Co-Founder and Scientific and Clinical Advisor
Chief Medical Officer
Age: 55
Chief Business Officer
Age: 53
Compensation as of Fiscal Year 2014.

G1 Therapeutics, Inc. Key Developments

G1 Therapeutics, Inc. Initiates Phase 1 Clinical Trial of G1T28-1

G1 Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications. The randomized, placebo-controlled, single ascending dose study will assess the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers. The study is being conducted in collaboration with PRA Health Sciences and is currently enrolling subjects in the Netherlands. Data collected from the study will inform dose and schedule for further development of G1T28-1, either as a bone marrow chemoprotectant or as an antineoplastic agent.

G1 Therapeutics, Inc. Announces Executive appointments

G1 Therapeutics, Inc. announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer. Dr. Malik will oversee the advancement of the company's lead CDK 4/6 inhibitor, G1T28-1, into a Phase I study for the reduction of chemotherapy-induced myelosuppression in the third quarter of this year. Mr. Mossinghoff will assume responsibility for G1's finances and business development efforts. Dr. Malik has more than 20 years of experience in drug development focused on oncology. Most recently, he served as Chief Medical Officer and management board member at Agennix AG. Mr. Mossinghoff has more than 25 years of domestic and international pharmaceutical industry experience. He has served as president of Integrated Oncology Solutions and Inspire Pharmaceuticals.

G1 Therapeutics, Inc. Appoints Mark Velleca as Chief Executive Officer

G1 Therapeutics, Inc. announced the appointment of Mark Velleca, M.D., Ph.D. as chief executive officer, effective immediately. Previously, Dr. Velleca was instrumental in founding, building, and leading CGI Pharmaceuticals up through its acquisition by Gilead Sciences in 2010. He most recently served as executive vice president at The Leukemia & Lymphoma Society (LLS).

Similar Private Companies By Industry

Company Name Region
Emissary Professional Group, LLC United States
PetLife Organic, Inc. United States
Merck Research Laboratories United States
Unimed Pharmaceuticals, LLC United States
Arcadia Rx LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact G1 Therapeutics, Inc., please visit www.g1therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.